Get started

Genomics

Twist Biosciences (TWST) AnalysisInnovation and Market Leadership: Twist Biosciences NASDAQ:TWST , a leader in synthetic DNA products, is set for substantial growth with its new Express Genes service, offering NGS-verified genes in just five to seven business days. This innovation is expected to strengthen Twist's market position and dominance. Growth Forecast and Market Expansion: The company forecasts a CAGR of over 28% through 2025, backed by a customer base of over 3,300 across various industries. Targeting multiple large addressable markets, Twist aims to sustain revenue growth for the foreseeable future. Investment Outlook: Bullish Outlook: We are bullish on TWST above the $41.00-$42.00 range. Upside Potential: With an upside target set at $76.00-$78.00, investors should consider Twist's innovative service offerings and robust growth projections as key drivers for potential stock appreciation. 📊🧬 Monitor Twist Biosciences for promising investment opportunities! #TWST #SyntheticDNA 📈🔍
NASDAQ:TWSTLong
by Richtv_official
BNGO Good News Coming Soon?NASDAQ:BNGO [/symbol With recent news, the future is looking good for BNGO. Biden signed ALS Law, this will result in $100m a year going into R&D for therapeutics and treatment; for ALS. Mayo clinic, a ALS Clinic, is already using BNGO. As well there is a projected 1500+ attendees at the moment for Symposiums2022. With pictures of the new system set to come out soon, On December 30, 2021, Bionano Genomics, entered into a Standard Industrial/Commercial Single-Tenant Lease with 6777 Nancy Ridge LLC. The Company agreed to lease from Landlord approximately 11,978 rentable square feet of laboratory and office space. Many fear that this was a costly play, not suitable for the current state of BNGO. Current Options Positions Short Calls - Strike 5.00 @ 1.21, 21-01-2022 Long Puts - Strike 2.00 @ 0. 05 , 21-01-2022 Short Calls - Strike 6.00 @0.21, 21-01-2022 Current Stock Positions @5.97 @4.00 @3.69 Average Price: 4.3425
NASDAQ:BNGO
by braydenboyko
$ARKG - Forget Noah, Cathies ARK will keep you afloat! Prime setup for $ARKG as we hit the midway point of Bloody September, the worst month for returns. We've already seen several pullbacks, and with quad witching coming on Sept 17, we're bound to see some volatility. I fully expect ARKG to fall a little further as the broader market bleeds, but come the quad witching hour, you'll start to see the tides shifting. Growth stocks are looking ready to launch off, and this fund which reflects not only biotech but also AI (as a lot of biotech companies stand to benefit from advancements in AI such as Googles Alpha Fold) is a prime example of the wave count that's prevalent across the board. Here we have: 1) W2 golden zone target between 80.50-76.79 (green) 2) Leg Y of W2, A = C equal legs target also matches 78.6% retracement of W2 (arrows) 3) Leg C of Y reaching its 14.6-23.6% fib targets between 76.34-75.34 (yellow) 4) Leg Y reaching its 23.6-38.2% fib targets between 77.63-75.70 (red) 5) Large volume profile node peaking around 76.30 This ETF should be in your growth portfolio, and now is the time to get your money ready. Remember, these funds have a 5 year time horizon. Ride the wave!
CBOE:ARKGLong
by ir-rizzle
1
NVTA on historic lowHello dear padawans. Short and sweet analysis on Invitae: $NVTA on long term support. It is also oversold. Given the lower shadow of current candle investors have strong appetite for current prices On the flip side one could venture reading the long term formation as a head and shoulders pattern. If you are a long term investor, buying here is a no brainer even if nvta drops more. Follow for more: If you want the best entry/exits just follow me, you won't regret. Thanks a lot! ***The ideas shared here are my opinion, not financial advise to place trades. Please do your own research before buying/selling stocks***
N
by Safe_Trades
BNGO round 2!!!!This play looks tempting ngl. NASDAQ:BNGO Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter. Last time I entered around $5 and avg'ED up till $5.6. Took Profit around $14 but this chart looks promising. Genomics is still an underrated sector and there are many supporters of its hot product -' The Saphyre system' Let's see how this runs. Good luck Entry - $7-$8 since it bottomed at $6.90. Set trailing SL of 15%. TP - $9-$10, since it might test resistance and bounce back down. Great company but burns through cash, so some major hyped event would need to occur for it to retest ATH. (Disclaimer this is not financial advice just my opinion)
NASDAQ:BNGOLong
by jackohgorman
1
CRSP short trade updates on weekly chartHere is my follow up update on original CRSP swing short trade idea I put up on January 14th. On this post, I am zooming out to weekly chart, looking at longer time frame to capture cyclical trends. Going back all the way to 2017 inception period, the higher than average volatilities are pretty easy to notice. It moves up really fast but also coming down. Every single time it has entered bear market or the sell signal is triggered, it has corrected well into double digit, easily averaging over 50%. In addition, RSI being overbought and high level PPO bearish cross overs are clear indication to trend reversal as well. Lastly, the week is too young still to comment yet but as of the end of today's session, it has taken down the up trend line as well on the weekly chart. There are plenty of time left in the week to recover the trend line but we shall see. It would be bullish if it can snap back above by the end of this week. I do not think CRSP will drop to my potential max targets without decent double digit correction in SPY and QQQ. I will comment on this post after the Friday close to see where it will be by then. If anyone has any thoughts either bullish or bearish, I would love to hear from you. Also, if you find it interesting, please follow me here. Have a good trade everyone, T.
NASDAQ:CRSPShort
by TK0421
2
BNGO Can we see this run till next earnings report ?The short volume ratio is decreasing which means good news for us. - Fintel Also looks like it's time for a reversal on the 1HR MACD so we could be in for a breakout with a high upside. All I'm hearing is nothing but good news associated with Bionano Genomics. However, we cannot fail to ignore the declining revenues every year. Keep an eye on this till the next earnings report. If the volume increase holds true, I'll be taking my profit around 15$ which should be a realistic target. If it runs further, 18$-20$ is definitely possible and will have to re-evaluate. Regardless, for now, we are Bullish! (Disclaimer) (This is not financial advice, just my opinion) NASDAQ:BNGO NASDAQ:BNGO
NASDAQ:BNGOLong
by jackohgorman
1
Crispr - DNA/Gene editing Technical Analysis Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in. The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma. An appropriate level to exit the trade then, would be below the 50sma. There also horizontal support as we fill the gap. Important Note: Earnings are on February 10th; so be aware of this if you plan to enter the trade. Opinion I believe this company is the future of gene editing. Check out a documentary of the company on Netflix called Human Nature. *It is more about how Crispr (DNA modification) works, than how the company makes money. Enjoy your weekend, dorfmaester
NASDAQ:CRSPLong
by dorfmanmaster